SCHEMBL24736634

SCHEMBL24736634

COC(=O)c1cc(C)cc(-c2ccc(O)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.57
CA12 O43570 5/20 0.56
CA1 P00915 5/20 0.56
CA2 P00918 5/20 0.56
CA9 Q16790 5/20 0.56
CA7 P43166 4/20 0.56
CA14 Q9ULX7 4/20 0.56
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
TDP1 Q9NUW8 2/20 0.47
LMNA P02545 2/20 0.46
GAA P10253 2/20 0.46
XDH P47989 2/20 0.46
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
NFKB1 P19838 1/20 0.46
GFER P55789 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
FUT7 Q11130 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13415725 0.90 CNR2 (0.60) CNR2CA12CA1CA2CA9
SCHEMBL16076889 0.90 CA1 (0.64) CNR2CA12CA1CA2CA9
SCHEMBL7248274 0.85 TSHR (0.55) CNR2CA12CA1CA2CA9
SCHEMBL1495726 0.83 CA12 (0.61) CNR2CA12CA1CA2CA9
SCHEMBL13415728 0.83 RXRA (0.54) CNR2CA1CA2RXRARXRB
SCHEMBL1495498 0.82 TDP1 (0.64) CNR2CA12CA1CA2CA9
SCHEMBL27176495 0.81 RXRA (0.67) CNR2CA12CA1CA2CA9
SCHEMBL4668655 0.80 CA1 (0.87) CA12CA1CA2CA9CA7
SCHEMBL8365053 0.80 CA1 (0.87) CA12CA1CA2CA9CA7
SCHEMBL18883017 0.78 SLC6A3 (0.55) CNR2KDM4EALDH1A1HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246948-A1 BENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT HK INNO.N CORPORATION (KR) 2024-07-25 US disclosed
EP-4342882-A1 BENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT HK inno.N Corporation (KR) 2024-03-27 EP disclosed
CN-117396463-A Benzamide derivative for preventing or treating cancer, method for preparing the same, and pharmaceutical composition containing the same as active ingredient 怡诺安有限公司 2024-01-12 CN disclosed
WO-2022245061-A1 BENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT 에이치케이이노엔 주식회사 2022-11-24 WO disclosed
WO-2022245061-A1 BENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT 에이치케이이노엔 주식회사 2022-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246948-A1 BENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT EGFR, ERBB2, TP53 CNR2 868/4885CA12 936/4885CA1 1510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.